Nordic Nanovector - Småprat 2 2020 - 2021 (NANOV) 1

[Martins]

Som nevnt flere ganger har de shortet hele røkla i biotech i Europa etter at den tredje bølgen med covid kom. De satser vel på utsettelser osv. i bransjen. Tror ikke det har noe spesielt med Nano å gjøre egentlig, men kan fort hende at de sitter med blodrøde tall i Nano ja.

[keislar]

Har hatt de samme shorterne i BGBIO også, sannsynligvis i lang tid nå. Noe dr… selvsagt men ved store nyheter vil shorten kunne bidra til høy kurs og liten plass i inngangsdøra. Så det er ikke bare negativt.

[Annab]

La oss “ha det litt moro”.

Hva tror du Nano kursen er etter Q1 og Archer?

Jeg tipper 49kr!

[hgsd300]

30-35 hvis opprettholdelse av guiding.

Holder Archer utenfor.

Tenker kursen holder seg rundt 22-24 før vi eventuelt får nyheter.

[JTHP]

Ditto

[Neonsun]

Fikk mail fra VPS nå, tegningsperioden starter 16:30 i ettermiddag så da kommer nok t-rettene opp i vps.no etter børsslutt.

[TekBot]

Nordic Nanovector ASA - Commencement of the subscription period in the repair offering

Not for release, publication or distribution, directly or indirectly, in the
United States of America, Canada, Japan or Australia

…

Vis børsmeldingen

THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS
TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS
CONTAINED HEREIN

Oslo, Norway, 25 March 2021

Reference is made to the stock exchange announcement from Nordic Nanovector ASA
(“Nordic Nanovector” or the “Company”) published on 23 February 2021 regarding
the successfully completed private placement raising approximately NOK 361
million in gross proceeds by issuance of 15,878,122 new shares (the “Private
Placement”), as well as the stock exchange announcement published on the same
day with key information about the contemplated repair offering of up to
2,699,280 additional new shares, each with a nominal value of NOK 0.20, at a
subscription price of NOK 22.75 per share (the “Repair Offering”).

Reference is further made to the extraordinary general meeting in the Company
held on 22 March 2021, amongst other resolving to grant an authorisation to the
Company’s board of directors to carry out the Repair Offering, as well as stock
exchange announcements on the same date regarding the board of directors’
decision to carry out the Repair Offering and the approval and publication of
the Company’s prospectus (the “Prospectus”).

The subscription period in the Repair Offering will commence on 25 March 2021 at
09:00 (CET) and will expire on 9 April 2021 at 16:30 (CEST). For further
information regarding the Repair Offering, please see the Company’s stock
exchange announcement from 22 March 2021 containing key information about the
Repair Offering. Additional information regarding the Repair Offering and
instructions regarding the procedures for subscription of the Offer Shares is
included in the Prospectus. Eligible shareholders will also receive a letter
from the Managers (as defined below) with further details on the number of
subscription rights granted to such eligible shareholder.

ABG Sundal Collier ASA, Carnegie AS and DNB Markets, a part of DNB Bank ASA, is
acting as managers for the Private Placement and Repair Offering (the
“Managers”). Advokatfirmaet Selmer AS is acting as legal advisor to the Company.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.

Important Notices

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful absent registration, or an
exemption from registration or qualification under the securities laws of any
jurisdiction.

This document is not for publication or distribution in the United States of
America, Canada, Australia or Japan and it does not constitute an offer or
invitation to subscribe for or purchase any securities in such countries or in
any other jurisdiction. In particular, the document and the information
contained herein should not be distributed or otherwise transmitted into the
United States of America or to U.S. persons (as defined in the U.S. Securities
Act of 1933, as amended (the “Securities Act”) or to publications with a general
circulation in the United States of America. This document is not an offer for
sale of securities in the United States of America. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under the
Securities Act. Nordic Nanovector does not intend to register any part of the
Private Placement in the United States of America.

There has not been made and will not be made any public offering of the
securities in the United States of America. Any public offering in the United
States of America would be made by means of a prospectus containing detailed
information about the company and management, as well as financial statements.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”) or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as “relevant persons”). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons.

Any person who is not a relevant person should not act or rely on this document
or any of its contents. Any offer of securities to the public that may be deemed
to be made pursuant to this communication in any member state of the European
Economic Area (each an “EEA Member State”) that has implemented Regulation
2017/1129 (the “Prospectus Regulation”) is only addressed to qualified investors
in that Member State within the meaning of the Prospectus Regulation.

The information contained in this document does not purport to be comprehensive.
None of the Managers, any of their respective subsidiary undertakings or
affiliates, or their respective directors, officers, employees, advisers or
agents accepts any responsibility or liability whatsoever for (whether in
contract, tort or otherwise) or makes any representation or warranty, express or
implied, as to the truth, accuracy or completeness of the information in this
document (or whether any information has been omitted from the document) or any
other information relating to the Company, its subsidiaries, affiliates or
associated companies, whether written, oral or in a visual or electronic form,
and howsoever transmitted or made available or for any loss howsoever arising
from any use of this document or its contents or otherwise arising in connection
therewith. The Managers disclaim any responsibility for any acts or omissions of
the Company, any of the Directors or any other person in connection with the
Private Placement.

The Managers are acting for the Company in connection with the Private Placement
and no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their respective clients or for providing
advice in relation to the Private Placement or any transaction or arrangement
referred to in this press release.

Solely for the purposes of the product governance requirements contained within:
(a) EU Directive 2014/65/EU on markets in financial instruments, as amended
(“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU)
2017/593 supplementing MiFID II; and © local implementing measures (together,
the “MiFID II Product Governance Requirements”), and disclaiming all and any
liability, whether arising in tort, contract or otherwise, which any
“manufacturer” (for the purposes of the MiFID II Product Governance
Requirements) may otherwise have with respect thereto, the securities described
in this press release have been subject to a product approval process, which has
determined that such securities are: (i) compatible with an end target market of
retail investors and investors who meet the criteria of professional clients and
eligible counterparties, each as defined in MiFID II; and (ii) eligible for
distribution through all distribution channels as are permitted by MiFID II (the
“Target Market Assessment”). Notwithstanding the Target Market Assessment,
distributors should note that: the price of the securities may decline and
investors could lose all or part of their investment; the securities offer no
guaranteed income and no capital protection; and an investment in the securities
is compatible only with investors who do not need a guaranteed income or capital
protection, who (either alone or in conjunction with an appropriate financial or
other adviser) are capable of evaluating the merits and risks of such an
investment and who have sufficient resources to be able to bear any losses that
may result therefrom. The Target Market Assessment is without prejudice to the
requirements of any contractual, legal or regulatory selling restrictions in
relation to the Transaction. Furthermore, it is noted that, notwithstanding the
Target Market Assessment, the Managers will only approach investors who meet the
criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute:
(a) an assessment of suitability or appropriateness for the purposes of MiFID
II; or (b) a recommendation to any investor or group of investors to invest in,
or purchase, or take any other action whatsoever with respect to the securities.
Each distributor is responsible for undertaking its own target market assessment
in respect of the securities and determining appropriate distribution channels.

This publication may contain specific forward-looking statements, e.g.
statements including terms like “believe”, “assume”, “expect”, “forecast”,
“project”, “may”, “could”, “might”, “will” or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of Nordic Nanovector
and those explicitly or implicitly presumed in these statements. Against the
background of these uncertainties, readers should not rely on forward-looking
statements. Nordic Nanovector assumes no responsibility to update forward
-looking statements or to adapt them to future events or developments.

Kilde

[Fartin]

Litt hjerte i halsen hver gang det kommer en melding fra nanov. Gleder meg til morgenen den starter med" nanov enters into"

[BuyHighSellLow]

Skulle ønske det var 26.03. Veldig avventende investorer, og dermed også veldig lite spennende kursutvikling og volum.

[amagad]

Vis oss Archer data så skal jeg (over)tegne meg jeg

[Oilimp]

@Fartin

meg til morgenen den starter med" nanov enters into"

Tar likegodt heller overskriften: “Nordic Nanovector has recieved a buyout offer of 2,5 billion dollars”

[Gordon_Gekko1]

For rask kortsiktig gevinst ville selvfølgelig et oppkjøp fra en BP aktør være bra, men på den annen side ville det være synd å selge alle mulige suksessbedrifter ut av landet. Vi burde heller se på hvordan bedriften kan bygges opp til å bli et konsern av betydelig størrelse! Slik langsiktig tenkning vil gi oss enda større gevinst! GG

[Intendanten]

Er for min del glad for at marathon’et er over om et drøyt år. Det har vært blytungt.
La oss håpe at vi passerer målstreken med begeistring og høyt hevet hode

[JTHP]

Litt av en tålmodighetsprøve med denne utviklingen for dere som har sittet med lenge.
Med avlesning av Paradigme, Archer og fortsatt positiv innrullering kommer dette til
å bli et særdeles spennende år for selskapet.

[hgsd300]

Kan nok bli en prøvelse hvis børsklimaet surner, blir lite med tiltakspakker fremover ser det ut til.

Bredt børsfall i USA etter Fed-uttalelse

[Neutral]

Godt Nano har greit med cash og flere triggere framover da Kan bli en fin aksje å trekke til

[TheObserver]

Nå skal jeg prøve meg på det som helt sikkert blir tidens jinx, men det ser ut som all teori har blitt snudd på hodet opp ned i NANO i forhold til tidligere emisjoner:

Der hvor man tidligere så emisjonskursen som et motstandsnivå man aldri brøt gjennom, har emisjonskursen denne gangen fungert som et gulv/støtte for videre kursnedgang.

Det gir vel et ganske greit signal om hvor mange sultne investorer det er der ute som gjerne ville inn i denne emisjonen og handler så raskt man ser kursen komme dit igjen.
Jeg har i alle fall ikke fått med meg at tilretteleggerne har fått noen GreenShoe til å støtte kursen!

Vi får se om teorien holder, eller om det ble den største jinx’en i 2021

[Merlin]

Hva er den faktiske verdien av aksjen i Nanov?

Jeg har gjort div. forsøk på beregning av denne verdien, og kommer til at minimum 300 kr. aksjen ila 12 mndr. i bud fra Big Pharma er aktuelt. Hva mener andre her på TI?

Her er grunnlaget for mitt overslag, som forutsetter at Betalutin blir godkjent og bla. at den bli SoC i 3linje FL, og også i 2 linje, samt får stor anvendelse i diverse typer NHL.

Man kan se på hva Rituximab solgte før de gikk av patent. Nå brukes Rituximab til andre ting også, men la oss anta at det selges for ca 6mrd. $ til NHL, og at Nanov i kombo med Rituximab kan overta en stor del av den delen som nå brukes på cellegifter og kommer ut på 40% av Rituximab. Da har vi peak sales for Archer-1 etc. for ca. 2,5 mrd.$.
Jeg skrev til sammenligning at om man antar at om Betalutin tar 10% av totalmarkedet for NHL utgjør det 2,9 mrd. $. Dette er antagelig lavt satt.
Innen 2 og 3 linje FL som er den nærmeste delen er et salg på 0,6 mrd. $ antatt relevant , men markedet totalt for Betalutin innen NHL da i hvert fall bør kunne utgjøre 2,5 mrd. $ på litt sikt (og også inkluderer former som MZL og DLBCL og antagelig også 1line FL). Jeg tar utgangspunkt i at Archer-1 kan bli standard of care for mye av NHL-behandlingen.

Hva blir da regnestykket?
Salg: 2,5x8,6 Nok/$ = 21,5 mrd Mok.
Si kostnadene er 50% (som antagelig er alt for høyt). Da har vi en netto årlig fortjeneste på 10,75 mrd. kr.
Trekk fra for neddiskontering. Med dagens lave rentenivå si netto da blir 8 mrd. kr. årlig.
Dra fra si 20% i risiko og markedsandel til CAR-T etc. ender det er på 6,5 mrd nok årlig.
Det gir en nåverdi på si 65 mrd. kr. som tilsier en kurs på minimum 650 kr. aksjen før skatt.

Det tilsvarer P/E på 10, ved P/E på 20 som ikke er irrelevant, dobles kursen.

Ved salg til Big Pharma når Paradigme er markedsgodkjent bør man kunne oppnå i det minste halvparten av dette. dvs minimum over 300 kr. pr. aksje, ila et års tid.

[anon57124368]

“Sperrene” blir spist. Ikke i nærheten av hva som skjedde for noen uker siden. Men at aksjer til 22.70 er billig, det tror jeg flere mener.

[Crypto1]

Selskapet burde dersom de er i besittelse av det, komme med informasjon som gir de 60 mill ekstra i kassa. Hvis ikke er jeg redd ulvene skrinlegger rep.emien.